Conference Proceedings
Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: Impact on adjuvant therapy
CL Creutzberg, A Leon-Castillo, SM de Boer, ME Powell, LR Mileshkin, HJ Mackay, A Leary, HW Nijman, N Singh, P Pollock, A Fyles, C Haie-Meder, VTHBM Smit, RJ Edmondson, H Putter, HC Kitchener, EJ Crosbie, M de Bruyn, R Nout, T Bosse
ANNALS OF ONCOLOGY | ELSEVIER | Published : 2019
Abstract
Background The PORTEC-3 trial investigated the benefit of combined adjuvant chemotherapy and radiotherapy (CTRT) versus radiotherapy alone (RT) for women with stage I-III endometrial cancer with high-risk features (HREC). Since the TCGA defined 4 molecular subgroups of EC with strong prognostic value, we investigated outcomes and impact of chemotherapy for each molecular subgroup using tissue samples from PORTEC-3 trial participants. Methods Paraffin-embedded tissues of 423 consenting patients (64% of 660) were collected. Immunohistochemistry for p53 and mismatch repair (MMR) proteins, and DNA sequencing for POLE pathogenic exonuclease domain mutations were done to classify tumours as p53 mu..
View full abstractGrants
Funding Acknowledgements
Koningin Wilhelmina Fonds voor de Nederlandse Kankerbestrijding (KWF).